Skip to main content

triptorelin pamoate (Decapeptyl® SR)

 

Status: Medicine does not meet criteria for AWMSG assessment

Excluded from appraisal by AWMSG as meets exclusion criteria 4. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information.

Medicine details

Medicine name triptorelin pamoate (Decapeptyl® SR)
Formulation 22.5 mg powder and solvent for suspension for injection
Reference number 1069
Indication

Treatment of patients with locally advanced, non-metastatic prostate cancer, as an alternative to surgical castration. Treatment of metastatic prostate cancer

Company Ipsen Ltd
BNF chapter Malignant disease & immunosuppression
Assessment type N/A
Status Medicine does not meet criteria for AWMSG assessment
Date of issue 06/06/2011
Follow AWTTC: